Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a ...

Ascendis Pharma will license its TransCon technology to Novo to develop therapies for metabolic and cardiovascular diseases.

Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo ...

In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ascendis Pharma (ASND – Research ...

Wells Fargo analyst Derek Archila maintained a Buy rating on Ascendis Pharma (ASND – Research Report) yesterday and set a price target of ...

Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.

Ascendis Pharma (ASND) has released an update. Ascendis Pharma has entered a collaboration with Novo Nordisk to license its ...

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...